ClinicalTrials.gg
RecruitingNCT04386018Updated Nov 13, 2020

A Registered Cohort Study of Inflammatory Demyelination Disease

An observational study in Demyelinating Autoimmune Diseases, CNS, sponsored by Ning Wang, MD., PhD.. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2020-11-13.

Sponsored by Ning Wang, MD., PhD. · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2022, 4 years 7 months ago, but the record still lists the study as recruiting.
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Sex
All
01

Study summary

This study will provide further insights into the natural course of Inflammatory demyelination disease including clinical features,progression, related antibody spectrum and drug treatment effect

02

Conditions studied

  • Demyelinating Autoimmune Diseases, CNS
03

In context

Demyelinating Autoimmune Diseases, CNS

26 studies on the registry are indexed under Demyelinating Autoimmune Diseases, CNS; 9 are open to participants now.

Browse Demyelinating Autoimmune Diseases, CNS studies →

Lead sponsor

Ning Wang, MD., PhD. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients with Inflammatory Demyelination Disease who are diagnosied in the First Affiliated Hospital of Fujian Medical Universtiy by two neurolgists

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatient or inpatient
  2. Meet the diagnostic criteria of Inflammatory Demyelination Disease.
  3. Voluntary participation and signed by the applicant or his/her family.

Exclusion criteria

Exclusion Criteria:

  1. Severe complications
  2. Poor prognosis (\<1 year survival)
  3. Severe mental disorder and inability to cooperate with the examination.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. The correlation between clinical phenotypes and Serum antibodies

    Different clinical subtypes of Demyelinating Autoimmune Diseases have different course and prognosis.It may be related to different serum antibodies.

    Time frame: from date of enrollment until the date of death from any cause,assessed up to 20 years

07

Study locations

1 of 1 sites recruiting
  • Department of Neurology,First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Recruiting
    • Wang Ning, PhD · Contactningwang@fjmu.edu.cn · 86-0591-87982772
    • Aiyu Lin, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2020 (actual). Primary completion is estimated for Apr 2022, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2020
First posted
May 13, 2020
StartActual
May 15, 2020
Primary completionEst.
Apr 1, 2022
CompletionEst.
Apr 1, 2025
Last update
Nov 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04386018
Lead sponsor
Ning Wang, MD., PhD.
Responsible party
Ning Wang, MD., PhD. (Director, First Affiliated Hospital of Fujian Medical University) — Sponsor-investigator
First posted
May 13, 2020
Start date
May 15, 2020
Primary completion
Apr 1, 2022 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Nov 13, 2020

Study contacts

Jin Bi, BA
Contact
2311306109@qq.com
86-13673527355

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion